Home › Carcinoma a cellule squamose della testa e del collo › Florida › Orlando
Studi clinici su Carcinoma a cellule squamose della testa e del collo a Orlando, FL
16 studi su Carcinoma a cellule squamose della testa e del collo cercano partecipanti presso sedi a Orlando e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
In reclutamentoFase 1
- Exelixis Clinical Site #48, Celebration · a 17 mi di distanza
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
In reclutamentoFase 3
- AdventHealth Medical Group Oncology and Hematology at Orlando, Orlando
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
In reclutamentoFase 3
- AdventHealth Orlando, Orlando
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
In reclutamentoFase 1
- Sara Cannon Research Institute Lake Nona, Orlando
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
In reclutamentoFase 1/2
- Florida Cancer Specialists - Lake Nona, Orlando
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
In reclutamentoFase 2
- Orlando Health, Orlando
SMP-3124LP in Adults With Advanced Solid Tumors
In reclutamentoFase 1/2
- Advent Health, Celebration · a 17 mi di distanza
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
In reclutamentoFase 1/2
- Clermont Oncology Center, Clermont · a 24 mi di distanza
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
In reclutamentoFase 1/2
- Sarah Cannon Research Institute (Lake Nona), Orlando
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
In reclutamentoFase 1
- Florida Cancer Specialists - Lake Nona, Orlando
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
In reclutamentoFase 1
- Florida Cancer Specialists, Orlando
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
In reclutamentoFase 3
- AdventHealth Medical Group Oncology & Hematology at Orlando, Orlando
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
In reclutamentoFase 1/2
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
In reclutamentoFase 1/2
- Florida Cancer Specialists-Lake Nona, Orlando
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
In reclutamentoFase 1
- Dren Investigational Site, Orlando
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
In reclutamentoFase 1/2
- Research Site 137, Orlando
- Research Site 118, Celebration · a 17 mi di distanza
Studi su Carcinoma a cellule squamose della testa e del collo in altre città
- Houston, TX47 studi
- Los Angeles, CA42 studi
- Boston, MA40 studi
- New York City, NY39 studi
- Nashville, TN39 studi
- St. Louis, MO28 studi
- Arlington, VA26 studi
- Philadelphia, PA26 studi
- Chicago, IL26 studi
- Atlanta, GA24 studi
- San Antonio, TX22 studi
- New Haven, CT22 studi
Altri studi a Orlando
- Cancro del polmone non a piccole cellule44 studi
- Obesità32 studi
- Cancro metastatico29 studi
- Sovrappeso27 studi
- Morbo di Alzheimer25 studi
- Diabete di tipo 225 studi
- Cancro (tutti i tipi)24 studi
- Cancro al seno23 studi
- Cancro ovarico22 studi
- Colite ulcerosa22 studi
- Cancro ai polmoni21 studi
- Cancro colorettale19 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.